Among the tested interventions, we report that (i) the MGMT inhibitor O6BG and PARPi olaparib and talazoparib inhibited the clonogenic survival of human GBM cells independently of their sensitivity to TMZ, (ii) the autophagy/mitophagy inhibitor CQ selectively re-sensitized U373-R cells to TMZ, and (iii) the ETC Complex III inhibitor antimycin A had unpredictable effects (Table S2). This evidence concerns the gene MGMT and glioblastoma.